BHV-0223 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03537807 (ClinicalTrials.gov)	June 2018	9/5/2018	Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)	BHV-0223 Expanded Access Protocol in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor Neuron Disease, Amyotrophic Lateral Sclerosis	Drug: Riluzole	Biohaven Pharmaceuticals, Inc.	NULL	No longer available	18 Years	N/A	All			NULL
2	NCT03520517 (ClinicalTrials.gov)	February 2, 2018	17/4/2018	Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS	Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor Neuron Disease, Amyotrophic Lateral Sclerosis	Drug: BHV-0223	Biohaven Pharmaceuticals, Inc.	Cognitive Research Corporation	Completed	18 Years	N/A	All	22	Phase 1	United States